+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response



Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response



Hepatology 46(6): 1732-1740



In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated interferon (PEG-IFN) alpha-2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for a fixed duration of 48 weeks (control group, n = 50) or for a variable duration (n = 318). In the variable-duration group, patients with undetectable HCV RNA at week 4 were treated for 24 weeks (group A, n = 69), patients with undetectable HCV RNA at week 12 were treated for 36 weeks (group B, n = 79), and the rest of the patients were treated for 48 weeks (group C, n = 160). The primary endpoint was SVR (undetectable HCV RNA 24 weeks after treatment cessation). Groups A-C and the control group had SVR rates of 86%, 76%, 56%, and 58%, respectively. After the study was controlled for predictors, a low baseline histologic grade and stage were associated with SVR (P < 0.029) in all groups. In addition, among patients in group C, older age (P = 0.04), a higher baseline body mass index (P = 0.013), and low baseline HCV RNA (P < 0.001) were also associated with SVR attainment. The incidence of adverse events and the rate of discontinuation were higher in patients in the variable-duration and fixed-duration groups treated for 48 weeks. In patients with chronic hepatitis C genotype 4 and undetectable HCV RNA at weeks 4 and 12, treatment with PEG-IFN alpha-2b and ribavirin for 24 weeks and 36 weeks, respectively, is sufficient.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 021534984

Download citation: RISBibTeXText

PMID: 17943989

DOI: 10.1002/hep.21917


Related references

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. Journal of Viral Hepatitis 16(8): 578-585, 2009

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. Clinical and Molecular Hepatology 18(3): 272-278, 2013

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Biomedicine and PharmacoTherapy 65(4): 303-306, 2011

A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate. Clinical Infectious Diseases 58(1): 130-133, 2014

Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin. Zhonghua Gan Zang Bing Za Zhi 24(3): 175-180, 2017

Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages. Przeglad Epidemiologiczny 60(4): 673-676, 2007

Prospective study on early virologic response to treatment with interferon alpha-2b plus ribavirin in patients with chronic hepatitis C genotype 1b. Hepatology Research 33(4): 285-291, 2005

Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C. Przeglad Epidemiologiczny 60(1): 71-77, 2006

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Journal of Gastroenterology and Hepatology 28(3): 443-449, 2013

Su1074 Meta-Analysis: Sustained Virologic Response (Svr) in Patients With Infection With Hepatitis C Virus Genotype 5 (Hcv-5) Versus Genotype 1 (Hcv-1) and Hcv Genotype 2/3 (Hcv -2/3) Treated With Interferon (Ifn) or Pegylated Interferon and Ribavirin (Peg Ifn+Rbv). Gastroenterology 146(5): S-981-S-982, 2014

Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scandinavian Journal of Gastroenterology 45(2): 250-255, 2010

Pegylated Interferon and Ribavirin Therapy for 24 Weeks Versus Shorter Duration for Patients with Hepatitis C Virus Genotype 2 and 3 Infection and Rapid Virologic Response: A Meta-Analysis. Gastroenterology 136(5): A-791, 2009

Protein Pathway Biomarkers Predicting Sustained Virologic Response (Svr) to Pegylated Interferon (Peg-Ifn) and Ribavirin (Rbv) in Treatment-Naive Genotype 1 Patients With Chronic Hepatitis C (Ch-C). Gastroenterology 138(5): S-783, 2010

M1781 Rapid Virologic Response Predicts Sustained Virologic Response in Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin Therapy. Gastroenterology 136(5): A-836-A-837, 2009

Prediction of early virologic response to treatment with 40kD pegylated -interferon alfa2a/ribavirin in patients with chronic hepatitis C. Gastroenterology 122(4 Suppl 1): A 626, 2002